Brind.

Bristol Myers' drug Opdivo is identified as a key component of the company's growth portfolio.

Steady: 1 in the last 7 days Updated yesterday

The latest in this situation

  1. Ono Pharmaceutical and Bristol-Myers Squibb collaborated to develop the drug Opdivo.

How it started

1 report, 1 independent, last reported Sep 2. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bristol Myers' drug Opdivo is identified as a key component of the company's growth portfolio.

How it developed

Newest first. Tap a step to see who reported it.
  1. Ono Pharmaceutical and Bristol-Myers Squibb collaborated to develop the drug Opdivo.Sub-event
  2. Opdivo is highlighted as a key drug in BMY's growth portfolio.1 source

Coverage

Newest first; wire copies grouped
  • ZacksWill Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth? Bristol Myers (BMY) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, Opdivo Qvantig, and Yervoy, among o